Summary: A sweeping, nationwide population-based cohort study utilizing one of the world’s largest healthcare databases has revealed a distinct biological link between neovascular age-related macular degeneration (nAMD) and an increased risk of developing specific cancers. The study tracked 334,091 individuals aged 50 and older, comprising 83,742 nAMD patients and 250,349 carefully matched controls, over a 10-year period. The data revealed that rather than a generalized, sweeping increase in overall malignancy, patients with nAMD exhibit a highly selective pattern of cancer susceptibility.
Specifically, these individuals face significantly elevated risks for thyroid, kidney, pancreatic, lung, bladder, and prostate cancers. The findings suggest that advanced retinal disease may serve as a clinical mirror for systemic vulnerabilities, driven by an overlapping “aging–inflammation–vasculature axis” that dictates how our bodies break down later in life.
Key Facts
- Massive Population Scale: By leveraging a massive national healthcare registry, investigators tracked over 330,000 participants for up to a decade, providing immense statistical power to isolate true epidemiological patterns from baseline noise.
- The Selective Target List: The increased risk is strictly selective. Individuals with nAMD demonstrated clear vulnerabilities to thyroid, kidney, pancreatic, lung, bladder, and prostate malignancies, while dozens of other common cancer types showed no statistical association whatsoever.
- The Thyroid Connection: One of the absolute strongest correlations identified in the 10-year tracking data was with thyroid cancer, where patients diagnosed with nAMD exhibited an approximate 24% higher risk compared to the healthy control group.
- The VEGF Paradox: Both nAMD and many aggressive tumors rely on Vascular Endothelial Growth Factor (VEGF) pathways to sprout abnormal, leaky blood vessels (angiogenesis). However, because many nAMD patients receive local anti-VEGF eye injections, researchers conclude that shared angiogenic pathways alone cannot fully explain the systemic link.
- The Common Biological Axis: Scientists point to a broader, systemic breakdown termed the aging–inflammation–vasculature axis. This includes chronic low-grade inflammation, cellular senescence (cells forgetting how to divide or die), intense oxidative stress, and structural remodeling of the extracellular matrix.
- Shared Polygenic Blueprints: Emerging genetic data discussed in the study highlights overlapping hereditary risk factors. Inherited vulnerabilities in complement immune system activation, lipid metabolism, and tissue regulation appear to independently trigger both retinal decay and tumor growth.
- No Cause for Screening Panic: The authors strongly emphasize that while the findings are statistically vital for understanding human biology, the risk increases are clinically modest. An nAMD diagnosis does not mean patients require specialized, aggressive cancer screenings outside of standard, age-appropriate medical checkups.
Source: Impact Journals
Neovascular age-related macular degeneration (nAMD) is one of the leading causes of severe vision loss in older adults.
Although the disease primarily affects the retina, researchers increasingly recognize that it may reflect broader biological processes associated with aging, including chronic inflammation, vascular dysfunction, and immune dysregulation. These same mechanisms have also been implicated in the development of several cancers, raising questions about whether the two conditions may be biologically connected.
To explore this possibility, investigators analyzed data from the Korean National Health Insurance Service, one of the world’s largest population-based healthcare databases. The study included 334,091 individuals aged 50 years and older, including 83,742 patients with nAMD and 250,349 matched controls without the disease. Participants were followed for up to 10 years, allowing researchers to evaluate both overall cancer incidence and risks for specific cancer types.
The analysis revealed that individuals with nAMD had a modest but statistically significant increase in overall cancer risk compared with matched controls. However, the increased risk was not observed across all cancers. Instead, patients with nAMD showed elevated risks for several specific malignancies, including thyroid, kidney, pancreatic, lung, bladder, and prostate cancers, while no significant associations were found for many other cancer types.
One of the strongest associations was thyroid cancer, for which individuals with nAMD had an approximately 24% higher risk. Increased risks were also observed for kidney, pancreatic, lung, bladder, and prostate cancers. These findings suggest that nAMD may be associated with a selective pattern of cancer susceptibility rather than a generalized increase in cancer risk.
The researchers explored several biological explanations for these observations. One possibility involves angiogenesis, the process through which new blood vessels form. Both nAMD and many cancers depend on signaling pathways involving vascular endothelial growth factor (VEGF), a key regulator of abnormal blood vessel growth. However, the authors suggest that shared angiogenic pathways alone are unlikely to fully explain the observed associations.
The study also points to broader aging-related mechanisms that may contribute to both conditions. Chronic low-grade inflammation, cellular senescence, immune dysregulation, oxidative stress, and extracellular matrix remodeling have all been implicated in the development of nAMD and cancer. The authors propose that these overlapping processes may form part of a common aging–inflammation–vasculature axis that influences disease susceptibility later in life.
In addition, the investigators discuss emerging evidence that nAMD and several of the associated cancers may share overlapping genetic risk factors. Biological pathways involving complement activation, lipid metabolism, inflammation, and extracellular matrix regulation have been linked to both retinal degeneration and tumor development, suggesting that common vulnerabilities may extend beyond the eye.
“These findings indicate that nAMD may serve as a clinical marker of systemic vulnerability to selected cancers, possibly through shared angiogenic, inflammatory, and polygenic mechanisms underlying aging-related disease susceptibility.”
According to the authors, the findings should be interpreted with caution. Although the observed increases in cancer risk were statistically significant, they were relatively modest and do not support specialized cancer screening solely on the basis of an nAMD diagnosis. Instead, the results suggest that nAMD may serve as a clinical indicator of broader systemic aging processes that also contribute to susceptibility to selected cancers.
Overall, this nationwide population-based study provides new evidence that neovascular age-related macular degeneration may be associated with increased risks of several specific cancers.
The findings support the growing recognition that aging-related diseases often share common biological pathways and highlight the importance of investigating vascular, inflammatory, and genetic mechanisms across multiple organ systems. Future research may help clarify how these shared aging processes contribute to both vision loss and cancer development.
Key Questions Answered:
A: Absolutely not. The study demonstrates a modest statistical correlation, not a direct, inevitable cause-and-effect guarantee. While the risk increase is highly important for scientists mapping out how the human body ages, the actual real-world increase in risk for any single individual remains relatively small. It simply means that the underlying cellular weaknesses that make a person vulnerable to severe retina damage can also make them slightly more susceptible to specific cell mutations elsewhere in the body.
A: No, and the study’s authors explicitly warn against doing this. Because the risk increases are modest and highly selective, an AMD diagnosis does not justify undergoing extra, stressful, or invasive cancer screenings that are not normally recommended. The best course of action is simply to maintain your standard, age-appropriate health screenings (like routine prostate exams or lung checkups) and keep your primary care doctor informed of your overall health status.
A: Anti-VEGF therapies for macular degeneration are delivered via tiny, highly localized injections directly into the vitreous gel of the eye. Because these treatments are designed to stay contained within the eye to fix the retina, they do not travel through the bloodstream in high enough concentrations to alter or block blood vessel growth in distant organs like the kidneys, pancreas, or thyroid. Furthermore, the study suggests that the link between these diseases goes far deeper than just VEGF, involving shared genetic vulnerabilities and chronic, whole-body inflammation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this cancer and visual neuroscience research news
Author: Ryan Braithwaite
Source: Impact Journals LLC
Contact: Ryan Braithwaite – Impact Journals LLC
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study” byHyeong Min Kim, Yoonjong Bae, Mina Kim, Hyungwoo Lee, and Hyewon Chung. Aging-US
DOI:10.18632/aging.206383
Abstract
Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults and is increasingly recognized as a manifestation of systemic aging involving vascular and inflammatory pathways.
Emerging evidence suggests that nAMD may also be linked to systemic diseases, including malignancies. Using data from the Korean National Health Insurance Service, we conducted a nationwide, population-based cohort study of 334,091 individuals (83,742 with nAMD and 250,349 matched controls) followed for up to 10 years.
Patients with nAMD showed a modest but significant increase in overall cancer risk (adjusted hazard ratio [aHR], 1.084; P < 0.001), with selectively elevated risks for pancreatic (aHR, 1.155; P < 0.001), lung (aHR, 1.128; P < 0.001), thyroid (aHR, 1.241; P < 0.001), renal (aHR, 1.177; P = 0.002), bladder (aHR, 1.121; P = 0.002), and prostate (aHR, 1.085; P < 0.001) cancers. No significant associations were observed for other malignancies.
These findings indicate that nAMD may serve as a clinical marker of systemic vulnerability to selected cancers, possibly through shared angiogenic, inflammatory, and polygenic mechanisms underlying aging-related disease susceptibility.
